HIND

Company Overview — What Does ReShape Lifesciences Inc. Do?

ReShape Lifesciences Inc., a medical device company, provides products and services that manages and treat obesity and metabolic diseases in the United States, Australia, Europe, and internationally. The company's product portfolio includes Lap-Band System, a minimally invasive long-term treatment of severe obesity and more invasive surgical stapling procedures, such as the gastric bypass or sleeve gastrectomy; and ReShape Vest system, an investigational, minimally invasive, laparoscopically implanted medical device that wraps around the stomach to enable weight loss in obese and morbidly obese patients without cutting or permanently removing portions of the stomach, or bypassing any portion of the gastrointestinal tract. It also offers ReShapeCare virtual health coaching program, a virtual telehealth weight management program that supports healthy lifestyle changes for all medically managed weight-loss patients; and ReShape Diabetes Bloc-Stim Neuromodulation, a technology that is in preclinical development for the treatment of type 2 diabetes mellitus. In addition, the company provides Obalon Balloon System, a swallowable capsule used to track and display the location of the balloon during placement. The company was formerly known as EnteroMedics Inc. and changed its name to ReShape Lifesciences Inc. in 2017. ReShape Lifesciences Inc. was incorporated in 2002 and is headquartered in San Clemente, California. ReShape Lifesciences Inc. (HIND) is classified as a micro-cap stock in the Healthcare sector, specifically within the Medical Equipment industry. The company is led by CEO Paul F. Hickey and employs approximately 50 people, headquartered in San Diego, California. With a market capitalization of $15M, HIND is one of the notable companies in the Healthcare sector.

ReShape Lifesciences Inc. (HIND) Stock Rating — Avoid (April 2026)

As of April 2026, ReShape Lifesciences Inc. receives a Avoid rating with a composite score of 30.0/100 and 1 out of 5 stars from the Blank Capital Research quantitative model.HIND ranks #4,054 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, ReShape Lifesciences Inc. ranks #710 of 838 stocks, placing it in the lower half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

HIND Stock Price and 52-Week Range

ReShape Lifesciences Inc. (HIND) currently trades at $2.28. The stock lost $0.02 (0.9%) in the most recent trading session. The 52-week high for HIND is $16.00, which means the stock is currently trading -85.8% from its annual peak. The 52-week low is $0.30, putting the stock 660.0% above its annual trough. Recent trading volume was 14K shares, suggesting relatively thin trading activity.

Is HIND Overvalued or Undervalued? — Valuation Analysis

ReShape Lifesciences Inc. (HIND) carries a value factor score of 12/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The price-to-book ratio stands at 3.94x, versus the sector average of 2.75x. The price-to-sales ratio is 3.16x, compared to 1.66x for the average Healthcare stock.

At current multiples, ReShape Lifesciences Inc. trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

ReShape Lifesciences Inc. Profitability — ROE, Margins, and Quality Score

ReShape Lifesciences Inc. (HIND) earns a quality factor score of 11/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -301.2%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -174.4% versus the sector average of -33.1%.

On a margin basis, ReShape Lifesciences Inc. reports gross margins of 51.4%, compared to 71.5% for the sector. The operating margin is -6378.7% (sector: -66.1%). Net profit margin stands at -6387.5%, versus -58.7% for the average Healthcare stock. Revenue growth is running at -98.2% on a trailing basis, compared to 10.6% for the sector. Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

HIND Debt, Balance Sheet, and Financial Health

ReShape Lifesciences Inc. has a debt-to-equity ratio of 73.0%, compared to the Healthcare sector average of 32.0%. Leverage is within a manageable range for the industry, though investors should monitor debt trends over time. The current ratio is 1.99x, suggesting adequate working capital coverage. Total debt on the balance sheet is $8,151. Cash and equivalents stand at $6M.

HIND has a beta of -1.75, meaning it is less volatile than the S&P 500, making it a relatively defensive holding. The stability factor score for ReShape Lifesciences Inc. is 33/100, suggesting elevated price swings that may be unsuitable for conservative portfolios.

ReShape Lifesciences Inc. Revenue and Earnings History — Quarterly Trend

In TTM 2026, ReShape Lifesciences Inc. reported revenue of $5M and earnings per share (EPS) of $-4.86. Net income for the quarter was $-11M. Gross margin was 51.4%. Operating income came in at $-15M.

In FY 2025, ReShape Lifesciences Inc. reported revenue of $319,714 and earnings per share (EPS) of $-4.86. Net income for the quarter was $-10M. Gross margin was 68.4%. Revenue grew -96.0% year-over-year compared to FY 2024. Operating income came in at $-10M.

In Q3 2025, ReShape Lifesciences Inc. reported revenue of $34,627 and earnings per share (EPS) of $-3.12. Net income for the quarter was $-9M. Gross margin was 52.1%. Revenue grew -98.5% year-over-year compared to Q3 2024. Operating income came in at $-9M.

In Q2 2025, ReShape Lifesciences Inc. reported revenue of $1M and earnings per share (EPS) of $-2.25. Net income for the quarter was $-3M. Gross margin was 48.2%. Revenue grew -36.8% year-over-year compared to Q2 2024. Operating income came in at $-3M.

Over the past 8 quarters, ReShape Lifesciences Inc. has demonstrated a growth trajectory, with revenue expanding from $2M to $5M. Investors analyzing HIND stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

HIND Dividend Yield and Income Analysis

ReShape Lifesciences Inc. (HIND) does not currently pay a dividend. This is common among smaller companies in the Medical Equipment industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

HIND Momentum and Technical Analysis Profile

ReShape Lifesciences Inc. (HIND) has a momentum factor score of 44/100, reflecting neutral trend characteristics. The stock is neither significantly outperforming nor underperforming the broader market on a momentum basis. The investment factor score is 40/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 69/100 reflects moderate short selling activity.

HIND vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, ReShape Lifesciences Inc. (HIND) ranks #710 out of 838 stocks based on the Blank Capital composite score. This places HIND in the lower half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing HIND against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full HIND vs S&P 500 (SPY) comparison to assess how ReShape Lifesciences Inc. stacks up against the broader market across all factor dimensions.

HIND Next Earnings Date

No upcoming earnings date has been announced for ReShape Lifesciences Inc. (HIND) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy HIND? — Investment Thesis Summary

The quantitative profile for ReShape Lifesciences Inc. suggests caution. The quality score of 11/100 flags below-average profitability. The value score of 12/100 indicates premium valuation. High volatility (stability score 33/100) increases portfolio risk.

In summary, ReShape Lifesciences Inc. (HIND) earns a Avoid rating with a composite score of 30.0/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on HIND stock.

Related Resources for HIND Investors

Explore more research and tools: HIND vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare HIND head-to-head with peers: HIND vs AZN, HIND vs SLGL, HIND vs VMD.